December 30, 2022 9:09 am | 1 minute read
- Silo Pharma Inc SILO reported preliminary data from his dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of antiarthritic drugs.
- Silo Pharma is pursuing a development plan using its liposomal joint-homing peptides as a potential therapy for rheumatoid arthritis.
- In the most recent phase of this ongoing animal study, tests were conducted to evaluate the disease suppressing effects of an SPU-21 peptide-driven anti-arthritis drug compared to the drug alone.
- Related: Silo Pharma publishes encouraging preclinical data for Alzheimer’s disease candidates.
- The drug used in the study was dexamethasone (DEX), a corticosteroid used for its anti-inflammatory and immunosuppressive effects.
- Previous results from the same study showed that the subcutaneous (SC) route of liposomal administration (small needle injection into shallow soft tissue just under the skin layer) is well suited for targeted drug delivery of antiarthritic drugs.
- Silo Pharma, in collaboration with the University of Maryland, Baltimore, is advancing the development of SPU-21 liposomal joint-homing peptides.
- Price promotion: SILO shares are up 40% to $4.80 during the premarket session on last Check Friday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
